The estimated Net Worth of Jeryl L Hilleman is at least $2.63 Million dollars as of 15 June 2023. Ms. Hilleman owns over 4,162 units of NovoCure Ltd stock worth over $264,463 and over the last 14 years she sold NVCR stock worth over $1,946,610. In addition, she makes $414,303 as Independent Director at NovoCure Ltd.
Jeryl has made over 24 trades of the NovoCure Ltd stock since 2011, according to the Form 4 filled with the SEC. Most recently she sold 4,162 units of NVCR stock worth $118,076 on 15 June 2023.
The largest trade she's ever made was exercising 51,200 units of NovoCure Ltd stock on 1 April 2019 worth over $764,416. On average, Jeryl trades about 5,449 units every 82 days since 2010. As of 15 June 2023 she still owns at least 15,349 units of NovoCure Ltd stock.
You can see the complete history of Ms. Hilleman stock trades at the bottom of the page.
Jeryl Hilleman serves as Independent Director of the Company. Ms. Hilleman recently retired from Intersect ENT, Inc., a healthcare equipment company, where she served as chief financial officer from 2014 to 2019. Prior to joining Intersect ENT, Ms. Hilleman was chief financial officer and secretary of Ocera Therapeutics, Inc. from 2013 to 2014. Ms. Hilleman also served as chief financial officer of Amyris, Inc., from 2008 to 2012, and as chief financial officer of Symyx Technologies, Inc. from 1997 to 2007. She has been Director of Minerva Neurosciences, Inc. since 2018 and director of SI-Bone, Inc. since 2019. From 2005, Ms. Hilleman served as a director of Xenoport, Inc., a biopharmaceutical company, until it was acquired in 2016. She holds A.B. in History, Brown University; M.B.A., Wharton Graduate School of Business.
As the Independent Director of NovoCure Ltd, the total compensation of Jeryl Hilleman at NovoCure Ltd is $414,303. There are 12 executives at NovoCure Ltd getting paid more, with William Doyle having the highest compensation of $8,286,100.
Jeryl Hilleman is 62, she's been the Independent Director of NovoCure Ltd since 2018. There are 5 older and 17 younger executives at NovoCure Ltd. The oldest executive at NovoCure Ltd is Prof. Yoram Palti, 83, who is the Founder & CTO.
Jeryl's mailing address filed with the SEC is C/O CUTERA, INC., 3240 BAYSHORE BLVD., BRISBANE, CA, 94005.
Over the last 9 years, insiders at NovoCure Ltd have traded over $237,132,855 worth of NovoCure Ltd stock and bought 164,174 units worth $2,198,429 . The most active insiders traders include Asaf Danziger, William Fwfd Ventures Fund ... und Michael J. Ambrogi. On average, NovoCure Ltd executives and independent directors trade stock every 7 days with the average trade being worth of $853,350. The most recent stock trade was executed by Ashley Cordova on 2 August 2024, trading 688 units of NVCR stock currently worth $13,856.
we are a commercial-stage oncology company developing a novel, proprietary therapy called tumor treating fields, or ttfields, for the treatment of solid tumor cancers. we count on the contributions of our talented team members who are committed to improving the lives of cancer patients. here at novocure, cancer patients and their families are – and have always been – at the core of our mission. we expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. we seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. we offer employment opportunities in the u.s., europe and asia.
NovoCure Ltd executives and other stock owners filed with the SEC include: